At a glance
ClinicalIndex Comparison RecordPhase 2Active· 113 enrolled
Drug / intervention
carmustine +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating carmustine, cytarabine, and 4 other interventions for Lymphoma. Active but no longer recruiting, targeting 113 participants across 126 sites.
Detailed Summary
The purpose of this study is to find out what effects (good and/or bad) treatment with chemotherapy and stem cell transplant compared with chemotherapy alone will have on primary CNS B-cell lymphoma. Currently the best treatment for patients with primary CNS B-cell lymphoma is not known.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)
Timeline
Phase 2Active
2012201320142015201620172018201920202021202220232024202520262027
First PostedJan 2012
Enrollment StartSep 2012
Primary CompletionDec 2020
TodayJul 2026
Study CompletionMay 2027
First PostedJan 18, 2012
Enrollment StartSep 1, 2012
Primary CompletionDec 10, 2020
Study CompletionMay 2, 2027
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 14.5 years ago
Interventions
carmustinedrug
Given IV
cytarabinedrug
Given IV
etoposidedrug
Given IV
thiotepadrug
Given IV
stem cell transplantprocedure
G-CSFdrug